Taylor & Morgan Wealth Management LLC Purchases 26,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 86.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 56,000 shares of the company’s stock after acquiring an additional 26,000 shares during the period. Taylor & Morgan Wealth Management LLC owned 0.08% of Perspective Therapeutics worth $179,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its stake in Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after acquiring an additional 298,778 shares during the last quarter. WealthPlan Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter worth $4,530,000. State Street Corp boosted its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares in the last quarter. Hills Bank & Trust Co acquired a new position in Perspective Therapeutics during the 3rd quarter worth approximately $13,722,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

CATX opened at $3.43 on Friday. The firm has a 50 day moving average price of $4.29 and a 200-day moving average price of $10.00. Perspective Therapeutics, Inc. has a twelve month low of $2.70 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million for the quarter. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Insider Activity

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 14,500 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was bought at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the purchase, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jonathan Robert Hunt bought 12,829 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the purchase, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. The trade was a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CATX. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Finally, UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.